Company profile
Surescreen Diagnostics Limited
Stay Safe and Secure with SureScreen Diagnostics COVID-19 Antigen Self Tests - Available Now for Direct Purchase | SureScreen Diagnostics
Established in 1996, SureScreen have been providing proactive, bespoke diagnostic solutions to organisations just like yours for nearly 25 years.
Corporate ownership
Updated 06 Jun 2026 16:52
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Memorandum Articles
IncorporationMA | Transaction MzUyMDI0MzEwOGFkaXF6a2N4 | Paper/PDF filed
Published 23 May 2026 22:43
Resolution
ResolutionRESOLUTIONS | Transaction WUYxSzNCV1dhZGlxemtjeA | Paper/PDF filed
Published 23 May 2026 22:43
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Full
Accounts AnalysedAA | Transaction MzQ0MDA4MTc3M2FkaXF6a2N4
Published 21 Oct 2024 07:01
Confirmation Statement With Updates
Confirmation-statementCS01 | Transaction MzQzNDYxOTA1NGFkaXF6a2N4
Published 06 Sep 2024 08:14
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
University of Nottingham and Surescreen Diagnostics Limited
1 Nov 2019 to 31 Jul 2023
To develop, demonstrate and implement a manufacturing system for producing personalised nutritional supplements at volume, for the ever-changing vitamin, nutrient and dietary supplement market.
The University of Nottingham and Surescreen Diagnostics Limited
1 Mar 2016 to 30 Sep 2019
To develop, transfer and embed analytical bioscience expertise in the areas of diagnostic technology.
University of Derby and Surescreen Diagnostics Limited
1 Nov 2015 to 31 Jul 2018
To establish capability in sports nutrition product develpment and testing.
Surescreen Diagnostics Ltd (Add on to KTP10040)
1 Oct 2015 to 31 Dec 2015
Awaiting Public Project Summary
Q-CANCER: development of a sample to result device for low cost, rapid tumour profiling
1 Jul 2013 to 30 Jun 2016
This project is concerned with the development of a fully integrated, low test cost, sample to result medical device that will enable a histopathologist (or a technician) to perform multiplex genotyping and tumour staging & profiling, within minutes, from formalin fixed &/or fresh tissue samples, providing a molecular adjunct to a histopathologist's stand...